Stay updated on Cyclophosphamide+Pembrolizumab in Metastatic TNBC Clinical Trial

Sign up to get notified when there's something new on the Cyclophosphamide+Pembrolizumab in Metastatic TNBC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cyclophosphamide+Pembrolizumab in Metastatic TNBC Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the completed study of cyclophosphamide followed by pembrolizumab in metastatic triple-negative breast cancer is now displayed, with study details, participant criteria, outcomes, and supporting documents.
    Difference
    54%
    Check dated 2026-11-07T14:52:26.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The site footer now identifies the release as v3.8.0 instead of v3.7.2; the page continues to show a 403 error rather than the study record.
    Difference
    0.2%
    Check dated 2026-10-31T15:42:47.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    The clinical trial record is displayed with details about the completed phase II study of cyclophosphamide followed by pembrolizumab for metastatic triple-negative breast cancer. It includes participant eligibility, study locations, treatment and outcome measures, and a study protocol document.
    Difference
    57%
    Check dated 2026-10-24T18:17:00.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2; the page still displays a 403 error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-17T22:10:39.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The site footer now displays revision v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-10T22:07:14.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study content with a standard error page and navigation elements, effectively blocking access to the study record.
    Difference
    19%
    Check dated 2026-09-19T22:01:11.000Z thumbnail image

Stay in the know with updates to Cyclophosphamide+Pembrolizumab in Metastatic TNBC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cyclophosphamide+Pembrolizumab in Metastatic TNBC Clinical Trial page.